Expert Guidance on Treatment Advances in Acute Myeloid Leukemia
Provided by Clinical Care Options, LLC, in collaboration with RealCME

Acknowledgment
Supported by educational grants from Astellas; Bristol Myers Squibb;
Genentech, a member of the Roche Group; and Jazz Pharmaceuticals, Inc.

Learning Objectives
Upon completion of this activity, learners should be able to:

• Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
• Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
• Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
• Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
• Identify/manage treatment-related toxicities associated with novel therapeutics

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Amir T. Fathi, MD, has disclosed that he has received consulting fees from AbbVie, Agios/Servier, Amgen, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, Foghorn, Forma, Forty Seven, Genentech, Ipsen, Kite, Kura Oncology, Morphosys, New Link Genetics, Novartis, Pfizer, Seattle Genetics, Takeda, Trillium, and Trovagene and funds for research support from AbbVie, Agios/Servier, and Celgene/Bristol Myers Squibb.

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, Bristol-Myers Squibb, Celgene, Genentech, Gilead Sciences, GlaxoSmithKline, Jazz, Kite, Kura Oncology, Mana, Novartis, Pfizer, Rafael, Stemline, and Takeda and fees for non-CME/CE services from Astellas, Dava Oncology, Jazz, Kura Oncology, Pfizer, and Stemline.

Naval G. Daver, MD, has disclosed that he has received funds for research support from AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Covance, Daiichi Sankyo, Forty Seven, Genentech, Glycomimetics, Hanmi, Immunogen, Incyte, Karyopharm, Newave, Nohla, Novartis, Pfizer, Servier, Sobi, Sunesis, and Trovagene and consulting fees from AbbVie, Agios, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Incyte, Jazz, Karyopharm, Novartis, Otsuka, and Pfizer.

Staff
CCO staff and planners have no relevant conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients AML.

Goal
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in integrating the most up to date guidelines and expert consensus into the care of their patients with AML.

Accreditation Information
 In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this live activity or enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
CCO designates this continuing education activity for 3.0 contact hour (0.30 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-118-H01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days. 

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours.

Program Medium
This program has been made available online.

Instructions for Credit
Participation in this activity should be completed in approximately 3.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2022 through April 21, 2023:

1. Register online at https://clinicaloptions.gathered.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity.
4. To claim the maximum amount of credit available, you must complete all of the following:

• Completion of the Baseline and Final assessment Modules: 0.5 credit hours
• Completion of the Self Study Modules: 1 credit hour
• Participate in Live Group Discussion 1: 0.5 credit hours
• Participate in Live Group Discussion 2: 0.5 credit hours
• Completion of Group Task 1: 0.25 credit hours
• Completion of Group Task 2: 0.25 credit hours

Credit can be claimed upon the completion of the Post Group Assessment, which is issued when groups close.